secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2023-09-18T23:59:59+00:00
Accession:  0001193125-23-237014
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma increases CEO base salary to $655,200, Executive Director to $350,784
--------------------------------------------------------------------------------

- Dr. Jerel Banks' (CEO) base salary raised to $655,200, effective Oct 1, 2023.
- Megan Boston's (Executive Director) base salary raised to $350,784 (AUD converted at 0.64 USD/AUD), effective Oct 1, 2023.
- Salary increases approved by Compensation Committee on September 13, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523237014/0001193125-23-237014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523237014/d552436d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-237014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer